

Highlights

- In conclusion, our study offers evidence for the role of epigenetic modification (miRNAs) on
- influenza vaccine-induced immunity. After validation, identified miRNAs may serve as potential
- biomarkers of immune response after influenza vaccination.

Introduction

 Influenza virus is a pathogen of major public health concern. Seasonal outbreaks can involve millions of cases in the United States and countless more worldwide. Influenza morbidity and mortality is increased in infants, young children, and the elderly. While the impact of influenza on human health has been ameliorated through the use of vaccination, vaccine efficacy rates vary greatly from year to year, indicating a need for the development of improved influenza vaccines, especially in those vulnerable populations. Systems biology studies and high-dimensional platforms are often utilized to comprehensively assess the human transcriptome in order to elucidate how protective immunity develops and is maintained after vaccination and to discover potential biomarkers of protective immunity. MicroRNAs (miRNAs) are 21-23 nucleotide sequences that modulate gene expression by binding to the 3' UTR of target mRNAs [1]. They control key biological processes and modulate innate and adaptive antiviral responses. Host miRNAs have also been demonstrated to affect viral gene expression and viral miRNAs have been shown to affect host gene expression [2, 3]. miRNA profiling studies of viral infection have highlighted the important regulatory effect of noncoding RNAs on immune response [2-4]. The goal of the study was to comprehensively assess lymphocyte-specific miRNA expression before and after influenza vaccination and to identify baseline/early miRNA biomarkers associated with, and perhaps predictive of, immune response to influenza vaccination.

Methods

 The methods described here are similar or identical to the ones in our previously published studies [5-8].

Study subjects

- A subgroup of 53 people was randomly selected from a previously recruited cohort of 159 older
- adults (50-74 years old, males and females) in good general health [7]. Individuals received the
- 2010-2011 trivalent inactivated influenza vaccine. This vaccine contained the
- A/California/7/2009 H1N1-like, A/Perth/16/2009 H3N2-like, and B/Brisbane/60/2008-like
- strains. Blood samples were collected before vaccination (Day 0) and at Day 3 and Day 28 post-
- vaccination. The Mayo Clinic Institutional Review Board approved all study procedures and
- written informed consent was obtained from each participant.
-

- Influenza A/California/7/2009/H1N1-specific hemagglutination inhibition (HAI) titers, viral
- 87 microneutralization assay (VNA) titers, and B cell ELISPOTs were performed using serum and
- PBMCs from each subject at each timepoint, as previously described [7, 8].
-

Cell purification and miRNA isolation

Cryopreserved PBMCs were thawed using standard procedures; stained with fluorescently

- labeled antibodies to CD3, CD4, CD8, CD19, and CD56 (BD Biosciences; San Jose, CA); and
- sorted by fluorescence-activated cell sorting using a FACSAria (BD Biosciences; San Jose, CA).
- CD4+ T cells, CD8+ T cells, CD3-CD56+ NK cells, and CD19+ B cells were sorted into cold
- PBS containing 2% fetal bovine serum. Total RNA, including miRNA, was extracted using
- miRNeasy Mini Kits (Qiagen; Valencia, CA) according to the manufacturer's instructions.
-

Immunologic Testing

Next Generation Sequencing

- cell subset. In total, 129 B cell, 127 CD4+ T cell, 105 CD8+ T cell, and 103 NK cell samples
- were carried forward for normalization and analysis. Normalization was done separately for each

 cell subset using the trimmed mean of M-values method [13] as implemented in the edgeR package [14] in R. A per cell subset post-normalization filter removed miRNA where the median count at each visit were all less than or equal to 4. All correlation analyses were computed using Spearman's correlation and the normalized values of miRNA expression data. Changes over time in miRNA were compared using Generalized Estimating Equations (GEE) [15] to account for the within-subject correlation. Per-miRNA negative binomial GEE models were fit in SAS© using miRNA as the response variable and the timepoint as the independent variable. The normalization offset and tagwise dispersion were estimated in edgeR [14]. False discovery rate control (BH procedure) was performed to correct for multiple testing and both p- values and FDR-adjusted p-values or q-values were reported. Multivariable models for each of the immune response variables were created using cross-validated, elastic-net penalized 132 regression models, with the tuning parameter $\alpha = 0.9$ [16]. Models were developed separately for each immune response outcome (HAI, VNA or B-cell ELISPOT); cell subset; and timepoint. The dependent variable in each model was the immune response outcome at Day 28 minus the response at Day 0 (log2 scale), while the normalized miRNA expression values were the independent variables. In order to reduce signal noise, only 25% of the miRNAs with the highest variability between subjects were considered in each model. Sex was included in the models as a covariate. The R package "multiMiR" [17] was used to identify genes representing validated targets of miRNAs of interest. Identified target genes were used in the "clusterProfiler" R package to identify enriched biological (KEGG) pathways regulated by the miRNAs of interest [18]. Results were reported with gene ratio, which represents the ratio of the input genes that are annotated in a term, and FDRs (q-values) of enrichment.

Results

miRNA profiles of lymphocyte subsets

 influence B and T cell receptor signaling and effector functions: MAPK, mTOR, PI3K-Akt, Ras signaling (Supplementary Fig. 2).

We also examined the 20 miRNAs with the highest median baseline expression level in each cell

type and found that the highly expressed miRNAs are largely overlapping (Supplementary Table

171 1). There were 22 miRNAs that were in the top 20 for at least two cell subsets (Supplementary

Table 1).

miRNA changes over time after vaccination

Overall, miRNA profiles in B cells, CD8+ T cells, and CD4+ T cells were stable and barely

176 changed after influenza vaccination. We did not discover significant expression changes $(q<0.1)$

in CD4+ T cells or B cells. In CD8+ T cells, the expression of only six miRNAs (miR-143-3p,

miR-152, miR-196a-5p, miR-548f, miR-9-3p, and miR-9-5p) decreased on Day 28 following

influenza vaccination. Interestingly, NK cell miRNA expression was much more dynamic and

changes were identified earlier, with 142 miRNAs exhibiting significant expression changes on

Day 3 following vaccination (Supplementary Table 2). Pathway analysis of the predicted targets

of the top NK cell miRNAs (n=24), indicated the regulation of the following pathways: ErbB

183 signaling pathway ($p=2.38E^{-06}$), Hippo signaling pathway ($p=1.98E^{-05}$), Wnt signaling pathway

184 (p=3.04E⁻⁰⁵), MAPK signaling pathway (p=7.40E⁻⁰⁵), Ras signaling pathway (p=0.001) and

mTOR signaling pathway (p=0.001) among others (data not shown).

miRNAs correlated with influenza vaccine response

Since the expression of miRNAs in B and T lymphocytes was stable across timepoints, we first

explored if the baseline expression level of multiple miRNAs in each cell type correlated with

Modeling of influenza vaccine-induced immune outcomes

 It is expected that multiple miRNAs work in concert to regulate immune response. Thus, a multivariable model, which jointly models the miRNAs in relation to the immune outcomes, could be a more powerful approach to identify predictive miRNAs compared to the "per miRNA" correlation analysis. Therefore, we next applied elastic net regularized linear regression modeling of immune outcomes as a function of miRNA expression. This joint modeling revealed

 several sets of miRNAs expressed in the different cell subsets that were collectively associated with and predictive of influenza vaccine-induced response outcomes. Figure 2 illustrates the correlation coefficients for the individual miRNAs baseline expression associated with each model. The top two models from our analysis efforts refer to baseline miRNA expression in CD4⁺ T cells correlated with both HAI (Fig. 2A) and VNA (Fig. 2B) responses, with extensive overlap in the identified miRNAs. Similarly, baseline miRNA expression in CD8+ and B cells correlated with VNA response and both models contained miR-4792 and miR-331-3p (Fig. 2C and D). For the two top models (Fig. 2A and B), we performed pathway enrichment analysis (as outlined in Statistical Analysis) on the putative target genes. These results are summarized in Fig. 3 and represent evidence for CD4+ T cell miRNA influence on the following biological processes and signaling pathways impacting immune response: carbohydrate and lipid metabolism, endocytosis and cytoskeleton regulation, cell adhesion and adherens junctions, TGF-β signaling, MAPK signaling, p53 signaling, PI3K-Akt signaling and C-type lectin receptor signaling pathways among others. Our predictive modeling efforts of immune outcomes as a 227 function of miRNAs post-vaccination revealed only a small number of $CD4^+$ T cell/NK cell miRNAs correlated with influenza-specific memory B cell ELISPOT response or HAI titer (Supplementary Fig. 3A, B and C).

Discussion

 Our study assessed miRNA expression before/after influenza vaccination in four major lymphocyte cell types (CD4+ T cell, CD8+ T cell, B cell, and NK cell) and demonstrated stable miRNA expression profiles over time (with the exception of NK cell miRNAs) and noticeably overlapping miRNAs expressed across different cell types. The interrogation of lymphocyte

 subset-specific miRNAs at baseline revealed miRNA control of both common and unique functional pathways. Among the targeted unique pathways are pathways closely involved in functional activity of specific cell types. These include the TGF-beta signaling pathway, apoptosis and the related to cell cycle control/longevity FoxO signaling pathway in CD4+ T cells; the PI3K-Akt signaling pathway important for the B cell development/differentiation in B cells; and the Ras signaling cascade, triggered downstream of B cell receptor to regulate B cell survival and function. miRNAs also regulated relatively common pathways linked to metabolism and proliferation, cellular senescence, cell adhesion-related pathways, MAPK signaling, p53 signaling, as well as endocytosis, cytoskeleton regulation, and anti-viral pathways. It is likely that the common pathways reflect the cellular housekeeping activity, cell cycle progression, cytoskeletal functions and metabolism necessary to support lymphocyte activation, differentiation, proliferation, and functional/immune activity. Although we expected to find more pronounced changes in cellular miRNA expression levels - 249 across timepoints relative to vaccination (baseline, Day 3, Day 28), we found that miRNAs in B cells, CD4+ T cells, and CD8+T cells were relatively stable over time following vaccination. Possible explanations of this observation include: sub-optimal timing of miRNA expression assessment following vaccination (i.e., miRNA expression changes were detectable at other timepoints); miRNA expression changes existed in antigen-specific cells and were missed with global miRNA expression assessment; or influenza vaccination did not alter significantly the host miRNA expression landscape. Interestingly, NK cells exhibited significant changes in miRNA expression at Day 3 post-vaccination relative to baseline. Several of these NK miRNAs have been implicated in biological activities that impact NK cell activity. Expression levels of miR152 changed significantly on Day 3 in NK cells, as well as on Day 28 in CD8+ T cells.

 miR152 has been demonstrated to control HLA-G expression and NK cell-mediated cytolytic activity [19].

 Another interesting finding, miR-125b-5p, has been reported to inhibit IRF4, which leads to increased expression of MICA a ligand for the NK cell activating receptor NKG2D [20]. Downregulation of this molecule after vaccination would promote enhanced NK cell activity. NK cells are important innate lymphocytes that have innate immune memory and are able to significantly regulate adaptive immune responses after vaccination [21]. For example, NK cell cytolytic activity was demonstrated to affect antigen persistence and/or target responding T cells after vaccination [21, 22]. Other NK cell functional activities (secretion of IFNγ and expression and activating/inhibitory receptors) have been linked to the stimulation of antigen-presenting cells following vaccination [23]. This suggests that changes in NK cell miRNA expression following vaccination can have direct or indirect effect on adaptive immune responses after influenza vaccination. Other miRNAs exhibiting NK cell expression changes include miR126- 5p, which has been implicated in the macrophage response to LPS [24] and in endothelial cell angiogenesis, [25] and miR148a-3p, which in concert with other miRNAs has been demonstrated to modulate plasma cell differentiation in B cells [26]. miR-339-5p has been shown to regulate lymphocyte tissue migration [27, 28] and to control inflammation by inhibiting IKK-β and IKK- ε activity [29]. Further investigation will be necessary in order to understand what role, if any, these NK cell miRNAs play in cell activation, proliferation, or immune function. Of great interest to vaccinology is the discovery of miRNAs that may regulate immune response and/or potentially serve as biomarkers of vaccine-induced immunity for inclusion in an immune signature predictive of optimal (or suboptimal) vaccine response. In this study, three baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443) were significantly negatively

 correlated with all three immune outcomes (HAI titer, VNA titer and memory B cell ELISPOT response) when data from all four cell types were analyzed (Fig. 1C and D). miR-150-3p has previously been reported to regulate key biological processes such as inflammation, apoptotic pathways and cell proliferation [30]. miR-150 overexpression has been found to profoundly impair formation of mature B cells and their functional activity with smaller effect on the development of T cells, granulocytes and macrophages [31]. Similarly, in our study, increased miR-150 expression in B cells was negatively correlated (p=0.00038) with memory B cell ELISPOT response after influenza vaccine, likely due to mature B cell suppression/suppression of germinal center memory B cell differentiation [32], while the increased expression in T cells (CD4+ and CD8+ T cells) was negatively correlated with the HAI/VNA titer. It was previously 292 established that the intracellular miR-150 expression in T cells (e.g., $CD4+T$ helper cells) is downregulated upon T cell activation to control key genes underlying T cell functions due to its quick extracellular release in exosomes [33, 34]. Importantly, extracellular miR-150 level (corresponding to the level of downregulation of intracellular miR-150 in T cells) has been established as a reliable serum marker of lymphocyte activation (T cell activation) [35]. Moreover, the serum level of miR-150 was found to be elevated in subjects following MF-59- adjuvanted 2009 influenza A (H1N1) vaccination with higher levels observed in subjects with higher antibody titers [33]. This is corroborated by our finding of negative correlation between the intracellular expression of miR-150 in T cells and influenza vaccine-induced HAI/VNA antibody responses. Thus, miR-150 expression emerges as a reliable biomarker of influenza vaccine-induced immunity as identified in a previous study [33] and ascertained by our findings. miR-629 has been investigated as a prognostic marker in cancer and has been implicated primarily in the regulation of proliferation, apoptosis, cell migration and alteration of TGF-

 beta/Smad signaling (via its target gene TRIM33) [36, 37]. Its expression has not been previously linked to immune response to vaccination/infection as suggested by our findings. miR-4443 has been connected to the regulation of key cellular signaling pathways such as the NF-κB, TGF-β and the Ras signaling pathways [38]. Increased expression of miR-4443 has been linked to dysfunction in T cells mediated via TNF receptor associated factor 4/TRAF4, and thus it is possible that this miRNA negatively impacts humoral immunity by impairing CD4+ T cell function [39]. On the other hand, the Ras GTPases serve as signaling checkpoints in antigen receptors, and Ras signaling (regulated in part by the expression of miR-4443) may play a key role in immune cell activation and function by engaging multiple downstream effectors [40, 41]. The Ras signaling pathway downstream of BCR is known to be a critical part of B cell proliferation, differentiation, antigenic activation and functional activity [42]. The Ras-ERK1/2 MAPK cascade is also tightly involved in Th2 cell differentiation [43], so it is possible that miRNA expression (miR-4443 and other miRNAs) regulating these signaling pathways may fine-tune critical antigen-driven cellular activities in B and T lymphocytes. Other miRNAs of interest demonstrated significant associations with HAI antibody titer (and not other immune outcomes) after influenza vaccination, but across several cell subsets. For example, the baseline expression of miR-331-3p was positively associated with HAI in B cells, CD4+ T cells, and NK cells (Fig. 2). Our predictive modeling efforts of baseline miRNA expression confirmed that indeed miR- 331-3p is an important biomarker of influenza vaccine-induced immunity as it was identified as a positive predictor of HAI/VNA antibody titer in CD4+ T cells, B cells and CD8+ T cells (Fig. 2). miR-331-3p has been demonstrated to inhibit proliferation and support apoptosis via regulating the PI3K/Akt and ERK1/2 pathways [44, 45]. It is possible that miR-331-3p expression regulates

 cell proliferation in several immune cell types and thus contributes to their functional activities following vaccination. For example, both signaling pathways (altered by the expression of miR- 331-3p) are key in regulating B cell metabolic activity, proliferation and differentiation upon antigenic stimulation and thus are likely to influence vaccine-induced immunity [46]. miRNAs of the miR-17–92 locus (i.e., miR-17 and miR-18a) in B and T cells (Fig.2) were also identified as being associated with post-vaccine HAI titer. These miRNAs play an important role in B cell development, differentiation, survival and regulation of class switching, and thus are intimately involved in B cell functionality [47]. The baseline cell expression of miR-15 and miR-223 was found to be associated with post-vaccine HAI titer and/or influenza virus-specific memory B cell ELISPOT response in our study. miR-15 was previously demonstrated to target Bcl2 and to regulate B cell survival, while miR-223 is enriched in the memory B cell compartment and regulates an important transcription factor (LMO2) critical for B cell differentiation, and has been also established as a regulator of activation-induced cytidine deaminase (AID) [48]. AID is an essential enzyme mainly expressed in germinal center B cells that plays a role in somatic hypermutation/antibody diversity and Ig class switching [49]. Thus, both miR-15 and miR-223 emerge as plausible regulators of B cell function and biomarkers of influenza. vaccine-induced humoral immunity. The expression of miR-34a-5p in CD4+ T cells was identified as a plausible predictor of influenza vaccine-induced antibody response (Fig. 2). The involvement of miR-34a- 5p in plasma cell differentiation (along with miR-125b-5p and miR-101-3p) has been previously demonstrated [26], but its role in regulating T cell functionality is still unclear. Interestingly, the expression of miR-125b-5p has also been identified as a predictor of VNA antibody response in both B cells and CD4+ T cells in our study.

 The top predictive models from our study (Fig. 2A and B) identified specific baseline miRNAs in CD4⁺ T cells as predictors (or factors associated with) of influenza vaccine-induced HAI/VNA antibody responses, with some overlap in the identified miRNAs (for the HAI and the VNA model). Interestingly, models involving miRNA expression post-vaccination resulted in less robust findings (Supplementary Fig. 3). The pathway enrichment analysis on the putative target genes regulated by the identified baseline miRNAs revealed the impact of several important signaling pathways in CD4+ T cells in shaping the influenza vaccine-induced immunity. These include TGF-β signaling, PI3K-Akt signaling, MAPK signaling, p53 signaling, TNF signaling and C-type lectin receptor signaling pathways. Basic cellular activities and functions (regulated by these miRNAs) were also identified as important and impacting influenza vaccine-induced humoral immunity: cell adhesion and adherens junctions, antiviral host response, carbohydrate and lipid metabolism, endocytosis and cytoskeleton regulation. The strengths of our study include the miRNA expression assessment in 4 purified cell subsets (B cells, CD4+ T cells, CD8+ T cells and NK cells) of subjects before/after influenza vaccination and the robust statistical modeling of influenza vaccine-induced immunity. The limitation is the lack of replication of the identified miRNA biomarkers/pathways in an independent cohort. Important next steps will be experimental validation of the identified miRNAs: co-expression studies of miRNAs and putative targets to provide experimental proof of specific miRNA- mRNA interactions; and experiments revealing how miRNAs modulate target protein expression and how this impacts immune response [50]. In conclusion, our study uncovered novel information regarding the complex genetic control of immune pathways, leading to better understanding of immune function regulation. The study

- also identified plausible predictive biomarkers of influenza vaccine-induced immune response
- outcomes, that warrant validation in future studies.

Data availability

- All data is available at ImmPort.org (SDY67).
-

Acknowledgements

- We would like to thank the subjects who volunteered to participate in our study. The study was
- funded by the National Institute of Allergic and Infectious Diseases of the National Institutes of
- Health (U01 AI 089859/Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune
- Profiling and R01AI132348), the Human Immunology Project Consortium Infrastructure and
- Opportunities Fund, and a grant from the Mayo Clinic Biomarker Discovery program (grant
- C4330915).
- The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials

being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to

AiZtech; AstraZeneca; Emergent; GlaxoSmithKline; Invivyd; Johnson & Johnson/Janssen;

Medicago; Medscape/WebMD; Merck & Co. Inc.; Moderna; NovaSource/NorthStar Energy;

Novavax; Ocugen; Regeneron; Sanofi; Syneos Health; and Valneva. Dr. Poland is an adviser to

the White House and World Health Organization on COVID-19 vaccines and monkeypox,

Figure Legends

Fig. 1 Baseline miRNA expression and its influence on humoral immune response outcomes

- following influenza vaccination
- **A.** Venn diagram of miRNAs expressed within each cell type**. B.** Correlation between baseline
- miRNA expression and HAI antibody titer following influenza vaccination. Correlation plot
- illustrating the associations between baseline miRNA and HAI antibody titer (Day 28 -Day0) for
- each cell subset (CD4+ T cell, CD8+ T cell, B cell, and NK cell) **C.** Baseline miRNAs
- significantly correlated with all humoral immune outcomes (change in HAI antibody titer, VNA

antibody titer and B cell ELISPOT response) for each cell subset. The color of the correlation

represents the direction (red, negatively associated, blue positively associated with the immune

- outcome). The size of the circle represents the strength of the correlation. The color intensity
- scale to the right of the figure is a scale for the Spearman's correlations with darker colors
- indicating stronger correlation. Blank cells indicate that the correlation with the specific miRNA

was zero in the associated cell type, and cells with a "?" indicate that the miRNA was not present

(not measured) in the cell type. *p <0.01, **p<0.001. **D.** miRNAs significantly correlated with HAI,

- VNA, and B cell ELISPOT. Correlations are with the immune response deltas (Day28 Day0).
- P<0.01 was used as the cut-off.

miR-150-3p hsa-miR-4443 hsa-miR-629-5p

D.

miRNA
(Day 0)

Α.

C.

437

438

439

440

441

Fig.2 Predictive modeling of baseline miRNA expression on influenza vaccine-induced

humoral immune outcomes

- Modeling was performed as described in Statistical Analysis. The baseline CD4+ T cell miRNAs
- predictive of influenza vaccine-induced HAI titer are depicted in **A**. and those predictive of VNA
- titer are depicted in **B**. The baseline B cell miRNAs and CD8+ T cell miRNAs predictive of
- influenza vaccine-induced VNA titer are depicted in **C** and **D**, respectively. The standardized
- linear regression coefficients are the estimated change in the response for a one standard
- deviation change in the associated miRNA expression. Positive coefficient values (bars
- extending to the right of the centerpoint of the x-axis) indicate that an increase in the miRNA
- expression is associated with an increase in the immune response outcome, while negative
- coefficient values (bars extending to the left of the centerpoint of the x-axis) indicate that as the

miRNA expression increases the immune. response outcome decreases.

Fig. 3 Pathway analysis of target genes regulated by baseline CD4+ T cell-specific miRNAs influencing influenza vaccine-induced HAI/VNA antibody titer

- Enrichment pathway analysis performed (see. Statistical Analysis) on the predicted gene targets of baseline CD4+ T cell miRNAs associated with **A.** HAI titer or **B.** with VNA titer. The bar length corresponds to the significance level of enrichment. Only pathways with q<0.0001 are
- included in the graph.

466

467 **Table 1. Cell type-specific miRNAs**

468

469 miRNAs with a median count of less than or equal to 4 were not included.

470

References

- 476 [1] Connerty P, Ahadi A, Hutvagner G. RNA Binding Proteins in the miRNA Pathway. Int J
- Mol Sci. 2015;17.
- [2] Atherton LJ, Jorquera PA, Bakre AA, Tripp RA. Determining Immune and miRNA
- Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types. Front Immunol. 2019;10:2323.
- [3] Oshiumi H. Circulating Extracellular Vesicles Carry Immune Regulatory miRNAs and
- Regulate Vaccine Efficacy and Local Inflammatory Response After Vaccination. Front Immunol. 2021;12:685344.
- [4] Abu-Izneid T, AlHajri N, Ibrahim AM, Javed MN, Salem KM, Pottoo FH, et al. Micro-
- RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. J Adv Res. 2021;30:133-45.
- [5] Haralambieva IH, Kennedy RB, Simon WL, Goergen KM, Grill DE, Ovsyannikova IG, et al.
- Differential miRNA expression in B cells is associated with inter-individual differences in
- humoral immune response to measles vaccination. PLoS One. 2018;13:e0191812.
- [6] Haralambieva IH, Painter SD, Kennedy RB, Ovsyannikova IG, Lambert ND, Goergen KM,
- et al. The impact of immunosenescence on humoral immune response variation after influenza
- A/H1N1 vaccination in older subjects. PLoS One. 2015;10:e0122282.
- [7] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Zimmermann MT, Grill DE, Oberg AL,
- et al. Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals. Vaccine. 2016;34:3993-4002.
- [8] Kennedy RB, Ovsyannikova IG, Haralambieva IH, Oberg AL, Zimmermann MT, Grill DE,
- et al. Immunosenescence-Related Transcriptomic and Immunologic Changes in Older
- Individuals Following Influenza Vaccination. Front Immunol. 2016;7:450.
- [9] Haralambieva IH, Zimmermann MT, Ovsyannikova IG, Grill DE, Oberg AL, Kennedy RB,
- et al. Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor
- Genes Associated with Measles-Specific Antibody Response after Vaccination. PLoS One. 2016;11:e0160970.
- [10] Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Zimmermann MT, Grill
- DE, et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing
- antibody response to measles vaccine. Hum Genet. 2017;136:421-35.
- [11] Sun Z, Evans J, Bhagwate A, Middha S, Bockol M, Yan H, et al. CAP-miRSeq: a
- comprehensive analysis pipeline for microRNA sequencing data. BMC Genomics. 2014;15:423.
- [12] Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately
- identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 2012;40:37-52.
- [13] Robinson MD, Oshlack A. A scaling normalization method for differential expression
- analysis of RNA-seq data. Genome Biol. 2010;11:R25.
- [14] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
- expression analysis of digital gene expression data. Bioinformatics. 2010;26:139-40.

- [15] Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes.
- Biometrics. 1986;42:121-30.
- [16] Hastie TT, Robert; Friedman, Jerome. The Elements of Statistical Learning: Data Mining,
- Inference, and Prediction. Second Edition ed: Springer; 2009.
- [17] Ru Y, Kechris KJ, Tabakoff B, Hoffman P, Radcliffe RA, Bowler R, et al. The multiMiR R
- package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res. 2014;42:e133.
- [18] Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment
- tool for interpreting omics data. Innovation (Camb). 2021;2:100141.
- [19] Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, et al.
- MiRNA-mediated control of HLA-G expression and function. PLoS One. 2012;7:e33395.
- [20] Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, et al. Inhibition of
- bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and
- sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-
- miR-125b interplay. J Hematol Oncol. 2016;9:134.
- [21] Cox A, Cevik H, Feldman HA, Canaday LM, Lakes N, Waggoner SN. Targeting natural
- killer cells to enhance vaccine responses. Trends Pharmacol Sci. 2021;42:789-801.
- [22] Rydyznski CE, Waggoner SN. Boosting vaccine efficacy the natural (killer) way. Trends
- Immunol. 2015;36:536-46.
- [23] Goodier MR, Riley EM. Regulation of the human NK cell compartment by pathogens and
- vaccines. Clin Transl Immunology. 2021;10:e1244.
- [24] Huang J, Zhu L, Qiu C, Xu X, Zhang L, Ding X, et al. MicroRNA miR-126-5p Enhances
- the Inflammatory Responses of Monocytes to Lipopolysaccharide Stimulation by Suppressing
- Cylindromatosis in Chronic HIV-1 Infection. J Virol. 2017;91.
- [25] Zhou Q, Anderson C, Hanus J, Zhao F, Ma J, Yoshimura A, et al. Strand and Cell Type-
- specific Function of microRNA-126 in Angiogenesis. Mol Ther. 2016;24:1823-35.
- [26] Tsai DY, Hung KH, Lin IY, Su ST, Wu SY, Chung CH, et al. Uncovering MicroRNA
- Regulatory Hubs that Modulate Plasma Cell Differentiation. Sci Rep. 2015;5:17957.
- [27] Shan W, Li J, Bai Y, Lu X. miR-339-5p inhibits migration and invasion in ovarian cancer
- cell lines by targeting NACC1 and BCL6. Tumour Biol. 2016;37:5203-11.
- [28] Zhou C, Lu Y, Li X. miR-339-3p inhibits proliferation and metastasis of colorectal cancer.
- Oncol Lett. 2015;10:2842-8.
- [29] Zhang Y, Wei G, Di Z, Zhao Q. miR-339-5p inhibits alcohol-induced brain inflammation
- through regulating NF-kappaB pathway. Biochem Biophys Res Commun. 2014;452:450-6.
- [30] Girardi C, De Pitta C, Casara S, Calura E, Romualdi C, Celotti L, et al. Integration analysis
- of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in modeled microgravity. Biomed Res Int. 2014;2014:296747.
- [31] Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in
- mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl
- Acad Sci U S A. 2007;104:7080-5.
- [32] Inoue T. Memory B cell differentiation from germinal centers. Int Immunol. 2023;35:565- 70.
- [33] de Candia P, Torri A, Gorletta T, Fedeli M, Bulgheroni E, Cheroni C, et al. Intracellular
- modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation.
- PLoS One. 2013;8:e75348.

- [34] Pagani M, Rossetti G, Panzeri I, de Candia P, Bonnal RJ, Rossi RL, et al. Role of
- microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation. Immunol Rev.
- 2013;253:82-96.
- [35] de Candia P, Torri A, Pagani M, Abrignani S. Serum microRNAs as Biomarkers of Human
- Lymphocyte Activation in Health and Disease. Front Immunol. 2014;5:43.
- [36] Yan H, Li Q, Wu J, Hu W, Jiang J, Shi L, et al. MiR-629 promotes human pancreatic
- cancer progression by targeting FOXO3. Cell Death Dis. 2017;8:e3154.
- [37] Ledoux D, Mereau A, Dauchel MC, Barritault D, Courty J. Distribution of basic fibroblast
- growth factor binding sites in various tissue membrane preparations from adult guinea pig.
- Biochem Biophys Res Commun. 1989;159:290-6.
- [38] Mao Y, Shen J, Wu Y, Wenjing R, Zhu F, Duan S. Aberrant expression of microRNA-4443 (miR-4443) in human diseases. Bioengineered. 2022;13:14770-9.
- [39] Qi Y, Zhou Y, Chen X, Ye L, Zhang Q, Huang F, et al. MicroRNA-4443 Causes CD4+ T
- Cells Dysfunction by Targeting TNFR-Associated Factor 4 in Graves' Disease. Front Immunol. 2017;8:1440.
- [40] Sadeghi Shaker M, Rokni M, Mahmoudi M, Farhadi E. Ras family signaling pathway in
- immunopathogenesis of inflammatory rheumatic diseases. Front Immunol. 2023;14:1151246.
- [41] Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005;118:843-6.
- [42] McLaurin JD, Weiner OD. Multiple sources of signal amplification within the B-cell
- Ras/MAPK pathway. Mol Biol Cell. 2019;30:1610-20.
- [43] Yamashita M, Shinnakasu R, Asou H, Kimura M, Hasegawa A, Hashimoto K, et al. Ras-
- ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-proteasome pathway. J Biol Chem. 2005;280:29409-19.
- [44] Zhao D, Sui Y, Zheng X. MiR-331-3p inhibits proliferation and promotes apoptosis by
- targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer. Oncol Rep. 2016;35:1075-82.
- [45] Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates
- expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014;116:67-75.
- [46] Jellusova J, Rickert RC. The PI3K pathway in B cell metabolism. Crit Rev Biochem Mol Biol. 2016;51:359-78.
- [47] Lou Z, Casali P, Xu Z. Regulation of B Cell Differentiation by Intracellular Membrane-
- Associated Proteins and microRNAs: Role in the Antibody Response. Front Immunol.
- 2015;6:537.
- [48] Zan H, Casali P. Epigenetics of Peripheral B-Cell Differentiation and the Antibody
- Response. Front Immunol. 2015;6:631.
- [49] Park SR. Activation-induced Cytidine Deaminase in B Cell Immunity and Cancers.
- Immune Netw. 2012;12:230-9.
- [50] Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA Targets: From Prediction Tools to
- Experimental Validation. Methods Protoc. 2020;4.
-